Myovant Sciences (MYOV) Files for $172.5M IPO

September 30, 2016 2:34 PM EDT
Get Alerts MYOV Hot Sheet
Trade MYOV Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Myovant Sciences Ltd. (NYSE: MYOV) filed a registration with the U.S. SEC for an IPO of its common stock. The proposed maximum offering price is $172.5 million.

Underwriters on the offering are Citigroup, Cowen and Company, Evercore ISI, and Barclays.

Myovant Sciences is a "clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women’s health diseases and other endocrine-related disorders. Our lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone, or GnRH, receptor antagonist." The company continued, "We are advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and advanced prostate cancer."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities

Citi, Barclays, Cowen & Co, IPO

Add Your Comment